Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will look at how the [18]FACBC goes into the lung nodules. This will hopefully lead to the development of better imaging techniques to look at lung nodules. [18]FACBC is not approved by the FDA (Food and Drug Administration). This study will help to determine if it should be approved by the FDA.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborator: NIHON MEDI-PHYSICS CO.,LTD.

Criteria

Inclusion Criteria:

1. Patients must be 18 years of age or older.

2. Patients with a history of cancer who have a solitary pulmonary nodule between 1-3 cm in short axis with clinical and CT characteristics warranting surgical removal (see below).

3. Clinical, laboratory, or diagnostic imaging findings on CT or 18F-FDG PET-CT do not suggest the possibility of the SPN being part of a metastatic process.

4. Ability to lie still for PET scanning

5. Patients must be able to provide written informed consent.

Exclusion Criteria:

1. Age less than 18.

2. Active carcinoma with known metastatic disease.

3. Size of primary lesion less than 1 cm or greater than 3 cm

4. Not a candidate for surgical resection or biopsy based upon clinical condition or discovery of metastatic disease which would preclude surgical therapy.

5. Inability to lie still for PET scanning

6. Cannot provide written informed consent